(19)
(11) EP 1 358 196 A2

(12)

(88) Date of publication A3:
04.09.2003

(43) Date of publication:
05.11.2003 Bulletin 2003/45

(21) Application number: 01991006.6

(22) Date of filing: 14.12.2001
(51) International Patent Classification (IPC)7C07H 19/00, C07H 21/02, C07H 21/04, C12N 15/00, G01N 33/00, G01N 33/53
(86) International application number:
PCT/US0147/903
(87) International publication number:
WO 0205/0300 (27.06.2002 Gazette 2002/26)
(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

(30) Priority: 20.12.2000 US 256800 P

(71) Applicant: Merck & Co., Inc.
Rahway, NJ 07065-0907 (US)

(72) Inventors:
  • FOLANDER, Kimberly, L.
    Rahway, NJ 07065-0907 (US)
  • LIU, Yuan
    Rahway, NJ 07065-0907 (US)
  • MCKENNA, Edward
    Rahway, NJ 07065-0907 (US)
  • SWANSON, Richard, J.
    Rahway, NJ 07065-0907 (US)

(74) Representative: Horgan, James Michael Frederic 
Merck & Co., Inc.,Terlings Park,Eastwick Road
Harlow,Essex CM20 2QR
Harlow,Essex CM20 2QR (GB)

   


(54) HUMAN HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CATION CHANNEL HCN3